SEC Says Biopharma's Cooperation Helped It Avoid Penalty
By Jessica Corso · December 3, 2024, 8:49 PM EST
A Houston biopharmaceutical company accused of misleading investors about the regulatory status of two cancer drugs agreed to settle the U.S. Securities and Exchange Commission's action against it on Tuesday without...
To view the full article, register now.